Peter Forsberg, MD, and Robert M. Rifkin, MD, FACP, discussed the trials supporting use of BCMA-targeted agents for relapsed/refractory multiple myeloma.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News Rifkin and Forsberg Review Trials of BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma back to News
minute read
Peter Forsberg, MD, and Robert M. Rifkin, MD, FACP, discussed the trials supporting use of BCMA-targeted agents for relapsed/refractory multiple myeloma.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.